Table 4.
QOL in VLNT using ad-hoc tools.
| Study | Year Published | Number of Patients | Stage | Lymphedema Site | Primary vs. Secondary | Surgical Procedure | Donor Site (Lymph Node Transplant) | Baseline QOL Measure Administered Pre-Operatively? | Average Follow-Up Time Regarding Subjective Assessment | QOL Measure | Percent of Patients with Subjective Improvement |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gharb et al. | 2011 | 21 | Not mentioned | UE | Secondary | VLNT (10 also liposuction) | Groin | Yes | 43.1 mo | Ad-hoc tool | Individual patient data not reported |
| Dionyssiou et al. | 2016 | 18 | ISL stage II (18) | UE | Secondary | VLNT | Groin | Yes | 12 mo | Ad-hoc tool | 100% |
| Coriddi et al. | 2017 | 15 | Not mentioned | UE (8), LE (7) | Secondary | VLNT | Jejunal Mesentery | Not mentioned | 9.1 mo | Ad-hoc tool | 86% |
| Nguyen et al. | 2017 | 42 | Modified ICG stage 3 (9), 4 (18), 5 (15) | UE (19), LE (24) | Secondary (37), Primary (2), not mentioned (3) | VLNT (55% also having LVA) | Omentum | Not mentioned | 14 mo | Ad-hoc tool | 83% |
ISL, international society of lymphology; UE, upper extremity; LE, lower extremity; LVB, lymphovenous bypass; VLNT, vascularized lymph node transplant; mo, months.